2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders DP1 Federal Grant

Home

RESEARCH

ARTICLES

RESOURCES

Government Jobs
Grant Forums

FAST GRANT SEARCH

FEDERAL GRANTS NEWSLETTER

2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1)

The summary for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.

Federal Grant Title:	2012 NIDA TRANSLATIONAL AVANT-GARDE AWARD FOR MEDICATION DEVELOPMENT FOR THE TREATMENT OF SUBSTANCE USE DISORDERS (DP1)
Federal Agency Name:	National Institutes of Health
Program Name:	Drug Abuse and Addiction Research Programs
Grant Categories:	Education Health
CFDA Number:	93.279
Funding Opportunity Number:	RFA-DA-12-010
Posted Date:	Jul 29, 2011
Creation Date:	Jul 29, 2011
Original Application Deadline:	Feb 21, 2012
Current Application Deadline:	Feb 21, 2012
Archive Date:	Mar 23, 2012
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:	Information not provided
Expected Number of Awards:	Information not provided
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Grant Description: The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of Substance-Use Disorders (SUDs). Through this FOA, the National Institute on Drug Abuse (NIDA) is committed to advancing the development of safe and efficacious medications for the treatment of SUDs stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Medications can be either small molecules or biologics. Biologics include vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the treatment of substance use (i.e., abuse or dependence) disorders and specific clinical manifestations of these disorders such as withdrawal, craving, or relapse.Applications that focus on the development of new formulations of marketed medications that are available for other indications, or new combinations of existing medications that hold promise for the treatment of SUDs, are also within the scope of this RFA.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-da-12-010.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • NIDA Research Center of Excellence Grant Program (P50); • Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21); • Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01); • Medications Development Centers of Excellence Cooperative Program (U54); • Drug Abuse Dissertation Research (R36); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Innovative Approaches and Technologies for Examining the Uncultivable Bacteria of the Oral...; • Research on the Role of Epigenetics in Social, Behavioral, Environmental and Biological Re...; • Pediatric Critical Care and Trauma Scientist Development Program (K12); • Evidence-based Demonstration Projects in Immunization (Admin Supp); • Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the...